Last Updated : May 21, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Kyprolis | Carfilzomib | Multiple Myeloma (relapsed) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kynmobi | apomorphine hydrochloride | Parkinson’s Disease | Withdrawn | |||
| Kynmobi | apomorphine hydrochloride | Parkinson’s disease | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kymriah | tisagenlecleucel | Relapsed or refractory follicular lymphoma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria | N/A | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Do not list | Complete | ||
| Kuvan | Sapropterin dihydrochloride | Phenylketonuria (PKU) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Koselugo | selumetinib | Neurofibromatosis type 1 | Reimburse with clinical criteria and/or conditions | Complete | ||
| Korsuva | difelikefalin | Chronic kidney disease | Do not reimburse | Complete | ||
| Komboglyze | Saxagliptin + metformin | Diabetes Mellitus, Type 2 | Withdrawn |
Last Updated : May 21, 2024